Gensciences

Focus: Gensciences is a China-based biotechnology company focused on biologics development, with a concentrated pipeline in rare disease hematology, specifically hemophilia treatments.

Rare Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Gensciences

AI assessmentNot Hiring

No open roles listed right now. Follow Gensciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

4 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

SS109

Hemophilia A With Inhibitor

Phase 1

Clinical Trials (1)

NCT05651061A Phase I of SS109 in Hemophilia A or and B With Inhibitors

Phase 1

Help build intelligence for Gensciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused pipeline with 9 active trials across hemophilia A indications, including 4 Phase 3 programs representing clinical validation momentum
Specialty focus on rare hematologic diseases offers deep clinical expertise and potential for meaningful patient impact
China-based biotech with potential access to underserved Asian markets for hemophilia treatments

Watch Out For

No current open positions (0 active job count) suggests limited hiring or potential organizational pause
Significant data gaps on funding, financials, employee count, and recent news create visibility risk about company stability and direction

Generated by Claude from Gensciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ADVATE

Severe Hemophilia A

Phase 1

Clinical Trials (1)

NCT04864743A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Phase 1

ADVATE

Hemophilia A

Phase 1

Clinical Trials (1)

NCT05251090A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ，Fc Fusion Protein for Injection

Phase 1

SS109

Male

Phase 1/2

Clinical Trials (1)

NCT06010953SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment

Phase 1/2

FRSW117

Severe Hemophilia A

Phase 2

Clinical Trials (1)

NCT05265286A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Phase 2

FRSW117

Severe Hemophilia A

Phase 3

Clinical Trials (1)

NCT06142552Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein

Phase 3

Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Hemophilia A

Phase 3

Clinical Trials (1)

NCT04845399Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A

Phase 3

FRSW107

Severe Hemophilia A

Phase 3

Clinical Trials (1)

NCT06136507Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A

Phase 3

Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Hemophilia A

Phase 3

Clinical Trials (1)

NCT04456387An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.

Phase 3

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 9 clinical trials

Top TAs: Rare Diseases

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Rare Diseases

9 pipeline

Marketed

Pipeline